ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L01

New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis

Neus Quilis1, Laura Ranieri2, Jose Sanchez-Paya2 and Mariano Andrés2, 1Hospital Universitario del Vinalopó, Elche, Spain, 2Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Date of first publication: October 4, 2018

Keywords: Allopurinol, Cardiovascular disease, febuxostat and gout, Late-Breaking 2018

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Late-Breaking Abstract Poster Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In those with prior CV disease, FBX showed an increased CV mortality risk over allopurinol (ALLO), leading to the issue of an FDA warning. Whether this also applies to individuals without prior established CV disease is unknown. We aimed to assess the risk of new CV events in gout patients after the prescription of xanthine-oxidase inhibitors (XOI) in clinical practice.

Methods: Inception cohort (Jan’14-Dec’17), enrolling patients with crystal-proven gout in whom XOI (ALLO or FBX) were initiated and had at least 6 months of follow-up. The primary outcome were new CV events [CV death; coronary heart disease (CHD); congestive heart failure (CHF); stroke; peripheral artery disease (PAP)] after XOI initiation. Comparison between ALLO and FBX was performed using Kaplan-Meier plots and log-rank test. To adjust for confounders, Cox regression models were built, for the whole sample and stratified by the pre-existence CV disease. Covariates were selected if associated with the outcome or if they showed a different distribution between XOI groups.

Results: 256 patients were analyzed, 213 treated with ALLO and 43 with FBX. 69 cases (27.0%) had established CV disease. 22 new CV events occurred in a median of 9.5 months (IQR 4.5-19.3): 13 CHF cases, 5 CHD, 2 strokes, and 2 PAP, leading to 7 CV deaths. 16 events occurred in patients with a prior CV (23.2%), six in those with no prior CV events (3.2%). Regarding XOI treatment, 13 events happened with ALLO (6.1%) and 9 with FBX (20.9%). Use of colchicine at the time of the event was comparable. A higher incidence of new CV events in those treated with FBX was seen (p<0.001, Kaplan-Meier plot). The simple Cox regression model confirmed a higher risk with FBX compared to ALLO (table), which persisted after adjustment. After stratification by prior CV disease, a significant CV risk with FBX was only detected in those with prior CV disease.

Conclusion: After adjustment for confounders, an excess risk of CV events is confirmed in patients with gout and prior CV disease treated with FBX. Whether this phenomenon relates to FBX itself needs further clarification.

*covariates: age, gender, hypertension, diabetes, dyslipidemia, smoking, established CV disease, baseline GFR, overweight, baseline SU, tophi, oligo/polyarthritis at presentation.

‡covariates: age, gender, hypertension, diabetes, dyslipidemia, smoking, baseline GFR, overweight, baseline SU, tophi, oligo/polyarthritis at presentation.


Disclosure: N. Quilis, None; L. Ranieri, None; J. Sanchez-Paya, None; M. Andrés, Menarini, Grunenthal, Horizon, 5.

To cite this abstract in AMA style:

Quilis N, Ranieri L, Sanchez-Paya J, Andrés M. New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/new-cardiovascular-events-in-patients-with-gout-treated-with-xanthine-oxidase-inhibitors-an-inception-cohort-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-cardiovascular-events-in-patients-with-gout-treated-with-xanthine-oxidase-inhibitors-an-inception-cohort-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology